APT featured in Netflix Series

August 2, 2020

News

Comments Off on APT featured in Netflix Series

APT is featured in episode 2 of the Netflix series Connected. Science journalist Latif Nasser investigates the surprising and intricate ways in which we are connected to each other, the world and the universe.

APT and John Haverty featured in the Boston Globe

July 10, 2020

News

Comments Off on APT and John Haverty featured in the Boston Globe

For scientists, clinical trials like these are a first try. For participants, they are often a last hope. At the brink of giving up, John Haverty turned to internet research. He was aware of phage treatment [the therapeutic use of bacteriophages to treat bacterial infections like Haverty’s], and he happened across Maryland-based Adaptive Phage Therapeutics.

Adaptive Phage Therapeutics Enters Agreement with Mayo Clinic to Commercialize a Phage Susceptibility Test

June 9, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Enters Agreement with Mayo Clinic to Commercialize a Phage Susceptibility Test

— Assay to rapidly match therapeutic phage to antibiotic-resistant infections — June 09, 2020 09:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a […]

Collaboration with Mayo Clinic

June 9, 2020

News

Comments Off on Collaboration with Mayo Clinic

GAITHERSBURG, Md.–Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a laboratory developed test for worldwide commercial availability by Mayo Clinic Laboratories (MCL). The PST will enable rapid identification […]

Infectious disease and the need for more options

June 2, 2020

News

Comments Off on Infectious disease and the need for more options

By learning from the past, we may have a much better arsenal against antimicrobial-resistant bacteria in the near future.

APT featured in Dutch Broadcast

May 25, 2020

News

Comments Off on APT featured in Dutch Broadcast

Adaptive Phage Therapeutics was featured in an April 28 broadcast in the Netherlands, Dokters van morgen, discussing the treatment of stubborn infections.  The discussion regarding APT begins at the 35 minute mark and features John Haverty (a patient helped by APT).

A Story of a Virus, Faith, and Hope That Saved His Life with John Haverty

April 2, 2020

News

Comments Off on A Story of a Virus, Faith, and Hope That Saved His Life with John Haverty

“Never Give Up on Your Life” – John Haverty. John Haverty is a chef, a family man, a patient who was battling a stubborn bacterial infection in his leg for over 10 years.  He wasn’t able to walk and put both feet on the ground for over 10 year.  Doctors at Mayo Clinic were about […]

FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

March 12, 2020

News

Comments Off on FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of PhageBank™, a personalized bacteriophage therapeutic for the treatment […]

FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

March 12, 2020

Press Releases

Comments Off on FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

— Three Clinical Sites to Enroll Patients with Recurrent and Complicated Urinary Tract Infections — March 12, 2020 10:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the U.S. Food and […]

Phages Provide Safety Net In Post-Antibiotic Era

February 13, 2020

News

Comments Off on Phages Provide Safety Net In Post-Antibiotic Era

February 13, 2020 | To fully appreciate the potential of Adaptive Phage Therapeutics (APT), it’s helpful to review history through the lens of company co-founder and Chief Scientific Officer Carl Merril. For nearly five decades, Carl has been championing the idea of using bacteriophages to treat infectious diseases—an idea for which he has been variably applauded, questioned, ignored, scolded, and, ultimately, vindicated.